MARKET

NVCR

NVCR

Novocure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

219.92
+3.64
+1.68%
Closed 18:11 06/14 EDT
OPEN
216.37
PREV CLOSE
216.28
HIGH
221.75
LOW
216.37
VOLUME
434.09K
TURNOVER
--
52 WEEK HIGH
221.75
52 WEEK LOW
55.40
MARKET CAP
22.74B
P/E (TTM)
2098.47
1D
5D
1M
3M
1Y
5Y
Insider Sale at NovoCure (NVCR) Continues Selling Trend
MT Newswires · 10h ago
Stocks That Hit 52-Week Highs On Monday
  During Monday's morning session, 255 companies made new 52-week highs.
Benzinga · 18h ago
Insider Trends: Insider Adds to Selling Trend at NovoCure
MT Newswires · 3d ago
We Think Shareholders Will Probably Be Generous With NovoCure Limited's (NASDAQ:NVCR) CEO Compensation
It would be hard to discount the role that CEO Asaf Danziger has played in delivering the impressive results at...
Simply Wall St. · 06/02 08:43
BRIEF-Saint-Petersburg Exchange Adds 43 International Stocks From June 1
reuters.com · 06/01 06:30
Top Healthcare Stocks for June 2021
These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2021.
Investopedia · 05/25 17:12
Novocure inks collaboration agreement with GT Medical Technologies
Novocure (NVCR) has entered into a clinical trial collaboration agreement with GT Medical Technologies to develop Tumor Treating Fields ((TTFields)) together with GT Medical's GammaTile Surgically Targeted Radiation Therapy ((STaRT))
Seekingalpha · 05/25 11:44
Novocure Announces Clinical Trial Collaboration With GT Medical Technologies To Evaluate Tumor Treating Fields Together With GammaTile Therapy In Recurrent Glioblastoma
Novocure (NASDAQ:NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical
Benzinga · 05/25 11:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVCR. Analyze the recent business situations of Novocure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVCR stock price target is 191.71 with a high estimate of 250.00 and a low estimate of 110.00.
EPS
Institutional Holdings
Institutions: 447
Institutional Holdings: 77.11M
% Owned: 74.57%
Shares Outstanding: 103.41M
TypeInstitutionsShares
Increased
99
5.19M
New
39
223.42K
Decreased
129
3.00M
Sold Out
65
1.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.36%
Healthcare Equipment & Supplies
+0.39%
Key Executives
Chairman/Executive Director
William Doyle
President/Chief Executive Officer/Director
Asaf Danziger
Vice Chairman/Director
Gabriel Leung
Chief Financial Officer
Ashley Cordova
Corporate Executive
Ely Benaim
Chief Operating Officer
Wilhelmus Groenhuysen
Vice President
Michael Ambrogi
General Counsel
Todd Longsworth
Other
Frank Leonard
Other
Pritesh Shah
Lead Director/Independent Director
William Vernon
Independent Director
Kinyip Leung
Independent Director
Jeryl Hilleman
Independent Director
David Hung
Independent Director
Kinyip Gabriel Leung
Independent Director
Martin Madden
Independent Director
Sherilyn McCoy
Independent Director
Timothy Scannell
No Data
  • All
  • Financials
  • Insiders
More
About NVCR
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.